On February 17, 2026, Perceptive Advisors revealed a purchase of 978,662 shares of Apogee Therapeutics (NASDAQ: APGE)with an estimated transaction value of $61.64 million based on the quarterly average price.
According to a February 17, 2026 SEC filing, Perceptive Advisors increased its stake in Apogee Therapeutics (NASDAQ: APGE) for 978,662 shares. The estimated value of the transaction was $61.64 million, based on the average share price during the fourth quarter of 2025. The fund ended the quarter with 2,330,651 shares, and the value of the position increased by $122.20 million, reflecting both new purchases and share price appreciation.
-
This purchase brings Apogee Therapeutics to 3.14% of Perceptive Advisors’ 13F AUM as of December 31, 2025.
-
Main participations after the presentation:
-
NASDAQ:PRAX: $588.30 million (10.8% of assets under management)
-
NASDAQ:CELC: $315.20 million (5.8% of assets under management)
-
NASDAQ:RYTM: $272.57 million (5.0% of assets under management)
-
NASDAQ:ASND: $230.60 million (4.2% of assets under management)
-
NASDAQ:ROIV: $173.28 million (3.2% of assets under management)
-
-
As of February 17, 2026, the stock was priced at $69.64, up 99.4% from last year, outperforming the S&P 500 by 78.67 percentage points.
|
Metric |
Worth |
|---|---|
|
Price (at market close 02/17/26) |
$69.64 |
|
Market capitalization |
3.82 billion dollars |
|
Net Income (TTM) |
($253.67 million) |
|
One year price change |
99.37% |
-
Apogee Therapeutics develops biologic therapies targeting atopic dermatitis, chronic obstructive pulmonary disease, and related immunologic indications, with lead candidates APG777 and APG808 in clinical development.
-
The company operates a biotechnology model focused on the research, clinical development and eventual commercialization of proprietary monoclonal antibody therapies; Revenue is expected to be derived from product sales following regulatory approval.
-
It is aimed at healthcare providers and patients affected by inflammatory and immunological diseases, with a primary focus on the dermatology and respiratory markets.
Apogee Therapeutics, Inc. is a biotechnology company specializing in the development of long half-life monoclonal antibodies for the treatment of atopic dermatitis and chronic obstructive pulmonary disease. The company leverages a portfolio of differentiated biologic candidates designed to address important unmet needs in immunology. Apogee’s strategy focuses on advancing its clinical programs toward commercialization, with the goal of establishing a competitive position in specific therapeutic markets.
Capital flows sometimes reveal more than the headlines, and when a biotech investor significantly adds to a name that has already doubled in a year, it indicates conviction not only in the momentum but in the durability of the platform.
Apogee Enterprises recently posted third-quarter net sales of $348.6 million, up 2.1% year-over-year, with adjusted EBITDA of $46.1 million and adjusted EBITDA margin of 13.2%. Diluted EPS was $0.77, or $1.02 on an adjusted basis. Management now expects fiscal 2026 sales of around $1.39 billion and adjusted diluted earnings per share of between $3.40 and $3.50.
This is not a large holding, at just over 3% of 13F assets, especially compared to larger positions in names like Praxis or Celcuity. But the position still suggests this is a calculated growth allocation, even if it is not a portfolio anchor.
Long-term investors should focus on project differentiation in atopic dermatitis and COPD, extended half-life antibody focus, and capital discipline. A stock that has performed around 100% can still rise if the clinical execution matches the ambition. The bet here seems sized for upside, not despair.